B Kasper1, S Sleijfer2, S Litière3, S Marreaud3, J Verweij2, R A Hodge4, S Bauer5, J M Kerst6, W T A van der Graaf7. 1. Interdisciplinary Tumor Center, Sarcoma Unit, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany. Electronic address: bernd.kasper@umm.de. 2. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 3. EORTC Data Centre, Brussels, Belgium. 4. Oncology TA Group, GlaxoSmithKline, Uxbridge, UK. 5. Sarcoma Center, West German Cancer Center, Essen, Germany. 6. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam. 7. Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Pazopanib recently received approval for the treatment of certain soft tissue sarcoma (STS) subtypes. We conducted a retrospective analysis on pooled data from two EORTC trials on pazopanib in STS in order to characterize long-term responders and survivors. PATIENTS AND METHODS: Selected patients were treated with pazopanib in phase II (n = 118) and phase III study (PALETTE) (n = 226). Combined median progression-free survival (PFS) was 4.4 months; the median overall survival (OS) was 11.7 months. Thirty-six percent of patients had a PFS ≥ 6 months and were defined as long-term responders; 34% of patients survived ≥18 months, defined as long-term survivors. Patient characteristics were studied for their association with long-term outcomes. RESULTS: The median follow-up was 2.3 years. Patient characteristics were compared among four subgroups based on short-/long-term PFS and OS, respectively. Seventy-six patients (22.1%) were both long-term responders and long-term survivors. The analysis confirmed the importance of known prognostic factors in metastatic STS patients treated with systemic treatment, such as performance status and tumor grading, and additionally hemoglobin at baseline as new prognostic factor. We identified 12 patients (3.5%) remaining on pazopanib for more than 2 years: nine aged younger than 50 years, nine females, four with smooth muscle tumors and nine with low or intermediate grade tumors at initial diagnosis. The median time on pazopanib in these patients was 2.4 years with the longest duration of 3.7 years. CONCLUSIONS: Thirty-six percent and 34% of all STS patients who received pazopanib in these studies had a long PFS and/or OS, respectively. For more than 2 years, 3.5% of patients remained progression free under pazopanib. Good performance status, low/intermediate grade of the primary tumor and a normal hemoglobin level at baseline were advantageous for long-term outcome. NCT00297258 (phase II) and NCT00753688 (phase III, PALETTE).
BACKGROUND:Pazopanib recently received approval for the treatment of certain soft tissue sarcoma (STS) subtypes. We conducted a retrospective analysis on pooled data from two EORTC trials on pazopanib in STS in order to characterize long-term responders and survivors. PATIENTS AND METHODS: Selected patients were treated with pazopanib in phase II (n = 118) and phase III study (PALETTE) (n = 226). Combined median progression-free survival (PFS) was 4.4 months; the median overall survival (OS) was 11.7 months. Thirty-six percent of patients had a PFS ≥ 6 months and were defined as long-term responders; 34% of patients survived ≥18 months, defined as long-term survivors. Patient characteristics were studied for their association with long-term outcomes. RESULTS: The median follow-up was 2.3 years. Patient characteristics were compared among four subgroups based on short-/long-term PFS and OS, respectively. Seventy-six patients (22.1%) were both long-term responders and long-term survivors. The analysis confirmed the importance of known prognostic factors in metastatic STS patients treated with systemic treatment, such as performance status and tumor grading, and additionally hemoglobin at baseline as new prognostic factor. We identified 12 patients (3.5%) remaining on pazopanib for more than 2 years: nine aged younger than 50 years, nine females, four with smooth muscle tumors and nine with low or intermediate grade tumors at initial diagnosis. The median time on pazopanib in these patients was 2.4 years with the longest duration of 3.7 years. CONCLUSIONS: Thirty-six percent and 34% of all STS patients who received pazopanib in these studies had a long PFS and/or OS, respectively. For more than 2 years, 3.5% of patients remained progression free under pazopanib. Good performance status, low/intermediate grade of the primary tumor and a normal hemoglobin level at baseline were advantageous for long-term outcome. NCT00297258 (phase II) and NCT00753688 (phase III, PALETTE).
Authors: M Van Glabbeke; A T van Oosterom; J W Oosterhuis; H Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: P D Stefanovski; E Bidoli; A De Paoli; A Buonadonna; G Boz; M Libra; S Morassut; C Rossi; A Carbone; S Frustaci Journal: Eur J Surg Oncol Date: 2002-03 Impact factor: 4.424
Authors: Philip A Harris; Amogh Boloor; Mui Cheung; Rakesh Kumar; Renae M Crosby; Ronda G Davis-Ward; Andrea H Epperly; Kevin W Hinkle; Robert N Hunter; Jennifer H Johnson; Victoria B Knick; Christopher P Laudeman; Deirdre K Luttrell; Robert A Mook; Robert T Nolte; Sharon K Rudolph; Jerzy R Szewczyk; Anne T Truesdale; James M Veal; Liping Wang; Jeffrey A Stafford Journal: J Med Chem Date: 2008-07-12 Impact factor: 7.446
Authors: Stefan Sleijfer; Monia Ouali; Martine van Glabbeke; Anders Krarup-Hansen; Sjoerd Rodenhuis; Axel Le Cesne; Pancras C W Hogendoorn; Jaap Verweij; Jean-Yves Blay Journal: Eur J Cancer Date: 2010-01 Impact factor: 9.162
Authors: J-Y Blay; M van Glabbeke; J Verweij; A T van Oosterom; A Le Cesne; J W Oosterhuis; I Judson; O S Nielsen Journal: Eur J Cancer Date: 2003-01 Impact factor: 9.162
Authors: S Sleijfer; T Gorlia; C Lamers; H Burger; J-Y Blay; A Le Cesne; M Scurr; F Collin; L Pandite; S Marreaud; P Hohenberger Journal: Br J Cancer Date: 2012-07-17 Impact factor: 7.640
Authors: Ana Ezponda; Ignacio González De La Huebra; Marta Calvo; Miguel Ángel Idoate; Isabel Vivas Journal: Oncol Lett Date: 2018-07-10 Impact factor: 2.967
Authors: Jose Duran-Moreno; Katerina Kampoli; Emmanouil I Kapetanakis; Maria Mademli; Nektarios Koufopoulos; Periklis G Foukas; Kostas Kostopanagiotou; Periklis Tomos; Anna Koumarianou Journal: In Vivo Date: 2019 Sep-Oct Impact factor: 2.155